CYP450 genotype and pharmacogenetic association studies: a critical appraisal

Pharmacogenomics
Rashmi R ShahRobert L Smith

Abstract

Despite strong pharmacological support, association studies using genotype-predicted phenotype as a variable have yielded conflicting or inconclusive evidence to promote personalized pharmacotherapy. Unless the patient is a genotypic poor metabolizer, imputation of patient's metabolic capacity (or metabolic phenotype), a major factor in drug exposure-related clinical response, is a complex and highly challenging task because of limited number of alleles interrogated, population-specific differences in allele frequencies, allele-specific substrate-selectivity and importantly, phenoconversion mediated by co-medications and inflammatory co-morbidities that modulate the functional activity of drug metabolizing enzymes. Furthermore, metabolic phenotype and clinical outcomes are not binary functions; there is large intragenotypic and intraindividual variability. Therefore, the ability of association studies to identify relationships between genotype and clinical outcomes can be greatly enhanced by determining phenotype measures of study participants and/or by therapeutic drug monitoring to correlate drug concentrations with genotype and actual metabolic phenotype. To facilitate improved analysis and reporting of association studies, ...Continue Reading

References

Mar 1, 1992·Clinical Pharmacology and Therapeutics·S H SindrupT C Tasker
May 1, 1990·Journal of Cardiovascular Pharmacology·W E HaefeliU A Meyer
Apr 1, 1987·Pharmacology & Toxicology·K BrøsenL Bertilsson
Aug 1, 1986·British Journal of Clinical Pharmacology·R BrinnS V Otton
May 1, 1985·Clinical Pharmacology and Therapeutics·N M WoolhouseR L Smith
Jan 1, 1983·European Journal of Clinical Pharmacology·S HögstedtA Rane
Jan 1, 1996·European Journal of Clinical Pharmacology·U JeppesenK Brøsen
Oct 23, 1997·Clinical Pharmacology and Therapeutics·W M O'NeilI W Wainer
Nov 14, 1997·Clinical Pharmacology and Therapeutics·M WadeliusA Rane
Jan 9, 1998·Drug Metabolism Reviews·E T Morgan
Apr 22, 1999·Journal of Clinical Psychopharmacology·C L AlfaroL Ereshefsky
May 26, 1999·Clinical Pharmacology and Therapeutics·S M Abdel-RahmanG L Kearns
Dec 10, 1999·Journal of Clinical Psychopharmacology·J A CarrilloJ Benítez
May 3, 2000·British Journal of Clinical Pharmacology·M L WilliamsI W Wainer
Jul 6, 2000·European Journal of Clinical Pharmacology·O O AkinyinkaA G Renwick
Feb 13, 2001·British Journal of Clinical Pharmacology·W M CaiY D Zhang
Dec 12, 2001·Clinical Pharmacokinetics·M H EnsomP Patel
Jun 18, 2002·The Medical Journal of Australia·Karin Nyfort-Hansen
Aug 2, 2002·Clinical Pharmacology and Therapeutics·Andrea GaedigkJ Steven Leeder
Sep 5, 2002·British Journal of Clinical Pharmacology·Benedetta C SallustioRaymond G Morris
Sep 30, 2003·Pharmacogenetics·Murray L BarclayJohn M Elliott
Oct 23, 2003·Pharmacopsychiatry·I IeiriK Otsubo
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·S M Killalea, H Krum
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Aug 4, 2004·Clinical Pharmacology and Therapeutics·Sebastian RaimundoUlrich M Zanger
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Issam ZinehJulie A Johnson
Feb 8, 2005·American Journal of Obstetrics and Gynecology·Timothy S TracyUNKNOWN National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units
May 7, 2005·Journal of Clinical Psychopharmacology·Michael KotlyarDavid E Adson
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew P GoetzJames N Ingle
Sep 12, 2006·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Vikas KumarTimothy S Tracy
Nov 23, 2006·Breast Cancer Research and Treatment·Matthew P GoetzJames N Ingle

❮ Previous
Next ❯

Citations

Jan 31, 2017·Journal of Global Antimicrobial Resistance·Amin Talebi Bezmin Abadi
Mar 13, 2018·Expert Opinion on Drug Metabolism & Toxicology·Mario CazzolaPaola Rogliani
Jun 20, 2018·Journal of Veterinary Pharmacology and Therapeutics·Marilyn N MartinezKatrina L Mealey
Oct 4, 2017·Annals of Human Biology·Francesco CaranoSusi Pelotti
Jan 4, 2019·European Archives of Psychiatry and Clinical Neuroscience·Ádám KissKatalin Monostory
Jul 9, 2016·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Andrea GaedigkJ Steven Leeder
Feb 21, 2018·Clinical Pharmacology and Therapeutics·Jesse J SwenUNKNOWN Dutch Pharmacogenetics Working Group (DPWG) of the Royal Dutch Pharmacists Association (KNMP)
Sep 11, 2020·Journal of Clinical Medicine·Sylvia D KlompJesse J Swen
Apr 3, 2021·Current Opinion in Pharmacology·Valentina MalafogliaAntonello Bonci
Mar 28, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ina LikoYee Ming Lee
Aug 8, 2021·British Journal of Pharmacology·Gaëlle MaglioccoYoussef Daali

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
urine collection
urine
blood draws

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved